Paediatric solid tumours arise from endodermal, ectodermal, or mesodermal lineages 1 . Although the overall survival of children with solid tumours is 75%, that of children with recurrent disease is below 30% 2 . To capture the complexity and diversity of paediatric solid tumours and establish new models of recurrent disease, here we develop a protocol to produce orthotopic patientderived xenografts at diagnosis, recurrence, and autopsy. Tumour specimens were received from 168 patients, and 67 orthotopic patient-derived xenografts were established for 12 types of cancer. The origins of the patient-derived xenograft tumours were reflected in their gene-expression profiles and epigenomes. Genomic profiling of the tumours, including detailed clonal analysis, was performed to determine whether the clonal population in the xenograft recapitulated the patient's tumour. We identified several drug vulnerabilities and showed that the combination of a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts tumours in vivo.
The overall engraftment efficiency was 45% (67/148) (Supplementary Table 1 ). The highest rates of engraftment were for high-grade sarcoma (83%), Wilms tumour (78%), retinoblastoma (70%), and rhabdomyosarcoma (65%) (Fig. 1b ). Recurrent tumour samples were significantly more likely to engraft (63%) than were diagnostic samples (37%) (P = 0.012; Fig. 1c ). There was a similar engraftment rate for samples from metastatic (53%) and primary (43%) sites (Fig. 1d ). The engraftment efficiency of samples obtained before chemotherapy was similar (50%) to that of samples obtained during chemotherapy (41%) (Fig. 1e ).
We performed haematoxylin and eosin (H&E) staining and immunohistochemistry on 51 O-PDX/patient tumour pairs (Extended Data Fig. 1a-d and Supplementary Table 2 ). Forty-nine of the tumours were evaluable for immunostaining, and 98% (48/49) were concordant between the O-PDX and the patient tumour. We scored the proportion of proliferating cells as measured by Ki67 immunostaining and dying cells as measured by activated caspase 3 immunostaining. We also performed tumour-type-specific protein immunohistochemical staining ( Supplementary Table 2 ). Neuroblastomas were stained for synaptophysin (Extended Data Fig. 1e ), rhabdomyosarcomas for myogenin and MyoD1, osteosarcomas for SATB2, Ewing sarcomas for FLI-1, high-grade sarcomas for vimentin, liposarcomas for S100, retinoblastomas for CRX, and rhabdoid tumours for INI1. In total, 1,173 slides were examined and evaluated microscopically. Generally, there was more proliferation (Ki67 + ) and less cell death (activated caspase 3 + ) in the O-PDXs than in the patient tumours. Each of the tumour-typespecific immunohistochemical stains were concordant between the patient tumours and the O-PDXs, except for SJRHB010928_X1, which was discordant by histopathological analysis.
Next, we surveyed 36 of the O-PDX tumours by transmission electron microscopy to characterize subcellular features of each tumour type ( Supplementary Table 2 ). Rhabdomyosarcomas had intracellular myofibrils; neuroblastomas had dense core vesicles; liposarcomas had large lipid droplets; and osteosarcomas had swollen endoplasmic reticulum and collagen deposits (Extended Data Fig. 1f-i) . Overall, the O-PDX tumours retained the cellular and subcellular features of the patient tumours ( Supplementary Table 2 ).
To determine whether the O-PDX tumours retain the somatic mutations in the patient tumours and whether they acquire additional mutations, we performed whole-genome sequencing and wholeexome sequencing of the O-PDXs and the matched patient tumour and germline samples (51 O-PDX/tumour pairs). For some samples, mutations were detected in the O-PDX but not in the patient tumour and vice versa (Extended Data Fig. 2 and Supplementary Table 3 ). These differences in detection of mutations may have been due to patient tumour purity, clonal changes, or sequence coverage. To distinguish between these possibilities, we performed capture enrichment and Illumina sequencing for 32,113 single-nucleotide variations (SNVs) identified across the sample cohort. The two mutations that were lost in the O-PDXs showed that both were due to shifts in the clonal composition. Among the 14 mutations that were gained in the O-PDXs, 6 were not surveyed because of copy number alterations, 2 were due to low tumour purity, 1 was due to insufficient coverage in the patient Individual clones are colour-coded and labelled C1-C4. a, Group 1 includes O-PDX tumours that preserved the clonal diversity and ratios of the patient tumours. b, Group 2 includes O-PDX tumours that preserved the clonal diversity and ratios of the patient tumours and continued to evolve in the mice. c, Group 3 includes O-PDX tumours that lost at least one clone in the patient tumour but were derived from a major clone. d, Group 4 includes O-PDX tumours that were derived from a minor clone (< 10%). e, Stack histogram of group 1-4 percentage clonal classification by tumour type. The numbers of samples in each group are indicated on the histogram. f, Comparison of clonal composition at initial engraftment and after passage 4. g, Comparison of multiple sublines from the same patient. Clonal composition across those sublines is indicated in the box. h, i, Drawing and photograph of the sampling of eight regions of the O-PDX tumours for analysis of regional clonal heterogeneity. j, Clonal analysis for all eight regions of the tumour in i showing clonal preservation across all eight regions. letter reSeArCH tumour, and the remaining 5 were bona fide new SNVs acquired in the O-PDX. Together, these data suggest that the O-PDXs faithfully maintain many features of the genomic landscape of the patient tumour from which they were derived.
To determine whether the clonal composition of O-PDX tumours changed relative to the patient tumours, we performed clonal analysis using the deep-sequence reads for all the SNVs across 42 of the patient tumours and their matched O-PDXs ( Supplementary Table 4 ). In total, 24% (10/42) of the O-PDXs accurately preserved the clonal composition of the patient tumour (group 1; Fig. 2a ). Thirty-one per cent (13/42) maintained the major clonal features of the patient tumour in the O-PDX but continued to clonally evolve in the mice (group 2; Fig. 2b ). Some O-PDX tumours (33%; 14/42) were derived from the major clone in the patient tumour but showed evidence of clonal loss (group 3; Fig. 2c ), and 12% (5/42) of the O-PDX tumours had clonal loss and were derived from a minor clone (< 10% of patient tumour) (group 4; Fig. 2d ). Osteosarcomas had the best clonal preservation and neuroblastomas had the least ( Fig. 2e ).
To determine whether the clonal composition of O-PDX tumours was stable with passages in vivo, we performed clonal analysis on 18 early-passage (initial engraftment or passage 1) and late-passage (passages 4-6) O-PDX tumour pairs ( Supplementary Table 4 ). Fortyfour per cent (8/18) of the O-PDX tumours had clonal preservation (group 1) at late-passage relative to early-passage ( Fig. 2f ), and a similar number (7/18) maintained the major clonal features of the earlypassage tumour but continued to evolve (group 2).
We also analysed the different O-PDX sublines and regional clonal heterogeneity in the tumour mass. The patient tumours were initially implanted in up to ten immunocompromised mice, and each tumour that grew was designated as a separate subline. For this analysis, we selected 11 O-PDX tumours with multiple sublines (range two to five sublines per tumour) and performed clonal analysis ( Supplementary  Table 4 ). All tumours were from initial engraftment or the first passage. Sixty-four per cent (7/11) of the O-PDX models had clonal preservation across two sublines (group 1; Fig. 2g ), and the remaining four had features of the major clone but showed some clonal evolution (group 2). To test the regional heterogeneity within tumours, we selected six O-PDX tumours and sampled eight regions of the tumour using a biopsy punch ( Fig. 2h , i). Clonal analysis of those samples showed clonal preservation (group 1; Fig. 2j and Supplementary Table 4 ).
To compare the gene-expression profiles of patient tumours with those of their matched O-PDXs, we performed RNA sequencing (RNA-seq) on all 102 samples that were analysed by whole-genome and whole-exome sequencing. We calculated the correlation coefficient from the log 2 -transformed values of fragments per kilobase of transcript per million mapped reads (FPKM) for each pair and grouped the data by tumour type (Extended Data Fig. 3a and Supplementary Table 5 ). There was no difference in the O-PDX/patient tumour correlation coefficients for the RNA-seq data by tumour type (P = 0.62, Kruskal-Wallis test). However, there was a significant inverse correlation between the patient tumour purity calculated from the whole-genome sequencing data and the O-PDX/patient tumour RNA-seq correlation coefficients for neuroblastoma and rhabdomyosarcoma (Extended Data Fig. 3b-d ). Patient tumours with low tumour purity contained more infiltrating normal cells than those with higher tumour purity. Upon transplantation into immunocompromised mice, the normal cells were lost, which could lead to a lower correlation for the RNA-seq of the patient tumour and matched O-PDX sample (Extended Data Fig. 3 ).
To determine whether the developmental origins were preserved in the tumours, we identified the genes that were significantly upregulated in neuroblastoma, osteosarcoma, and rhabdomyosarcoma (Supplementary Table 5 ). The most significantly enriched pathways in neuroblastoma were those for neuronal development and homeostasis, rhabdomyosarcomas were enriched for myogenesis, and osteosarcomas were enriched for pathways in bone development and collagen production. To determine whether this association was reflected in the epigenetic landscape of the tumours, we performed chromatin immunoprecipitation followed by sequencing (ChIP-seq) for nine histone marks (H3K27Ac, H3K27me3, H3K36me3, H3K4me1, H3K4me2, H3K4me3, H3K9-14Ac, H3K9me2, H3K9me3), RNA Pol II, CTCF, and BRD4. We used chromatin prepared from a representative embryonal rhabdomyosarcoma (ERMS, SJRHB000026_ X1), an alveolar rhabdomyosarcoma (ARMS, SJRHB010463_X16), an osteosarcoma (SJOS001112_X1), and a neuroblastoma Osteosarcoma SP7
Rhabdomyosarcoma SP7 (SJNBL046_X). We performed ChIP-seq from biological replicates of each sample for a total of 96 ChIP-seq libraries. We performed chromatin hidden Markov modelling (chromo-HMM) 12 using 16 states ( Fig. 3a, b ). States 1-6 had epigenetic marks consistent with enhancers and active promoters; state 7 contained epigenetic marks of bivalent (H3K27me3/H3K27Ac) poised promoters/ enhancers; and states 8-10 included epigenetic marks of gene bodies. State 11 comprised polycomb-repressed genomic regions, and state 12 was an empty state lacking ChIP-seq peaks in our analysis. States 13 and 14 consisted of heterochromatin, and state 15 represented repressed chromatin (H3K27me3 and H3K9me3). The CTCF insulator protein-bound regions were enriched in state 16. Most lineage-specific genes that were expressed at high levels in a particular tumour type had tumour-specific enrichment in active chromo-HMM states (states 1-6) ( Fig. 3c and Extended Data Fig. 4 ). The chromo-HMM state for those genes in the tumour types where they were not expressed were often classified as empty (chromo-HMM state 12) or H3K27me3-repressed (chromo-HMM states 7, 11, 15) ( Fig. 3c and Extended Data Fig. 4 ). For example, the SP7 gene was expressed in osteosarcoma but not in neuroblastoma or rhabdomyosarcoma (Fig. 3d ). The promoter of the SP7 gene had an HMM state of a strong active promoter (state 1) in osteosarcoma, but it was silent in rhabdomyosarcoma ( Fig. 3d, e ). Similar patterns were found for genes expressed specifically in rhabdomyosarcoma and neuroblastoma (Extended Data Fig. 4 ). Together, these data suggest that the lineagespecific developmental program is strongly preserved in the epigenome of paediatric solid tumours ( Supplementary Table 5 ).
To determine whether our O-PDX tumours demonstrated differential drug sensitivity, we developed primary culture conditions for each tumour type for high-throughput drug screening.
We screened 16 rhabdomyosarcomas, 8 osteosarcomas, 4 neuroblastomas, 1 Ewing sarcoma, and 1 rhabdoid tumour. For comparison, we also included 21 paediatric solid tumour cell lines ( Supplementary  Table 6 ); 156 drugs were used in this analysis for a total of over 500,000 individual data points. Of the 1,960 plates screened, 49 (2.5%) had Z′ < 0 and were excluded from further analysis. Of the remaining plates, the average Z′ was 0.57, and 95% of all plates had Z′ between 0.27 and 0.82 (Extended Data Fig. 5a ). Drugs with the same mechanism of action had similar activity across O-PDXs and cell lines (Extended Data Fig. 5b ). Mutations in signal transduction pathways were predictive of tumour response in a subset of tumours (Extended Data Fig. 5c ). Validated data were entered into a central database (https://stjude.org/ cstn-drug-sensitivity), and curve fitting was performed to determine the half-maximum effective concentration (EC 50 ) of each drug for each tumour ( Supplementary Table 6 ). Growth rate can influence drug sensitivity for some classes of drugs in high-throughput screening experiments 13 , so we corrected for differences in growth rate (Supplementary Table 6 ). The most commonly used broad-spectrum chemotherapeutics were active across several tumour types, and histone deacetylase and proteasome inhibitors were particularly active across tumour types ( Supplementary Table 6 and https://stjude.org/cstn-drug-sensitivity).
Among the drugs with tumour subtype-specific activity, the WEE1 inhibitor AZD1775 (MK-1775) was of particular interest for rhabdomyosarcoma because a phase I study of it with irinotecan (IRN) was recently completed by the Children's Oncology Group (COG trial NCT02095132). This is important because IRN and vincristine (VCR) are used to treat recurrent rhabdomyosarcoma; and given the sensitivity of rhabdomyosarcoma O-PDXs to AZD1775, combining it with IRN and VCR may be justified for future clinical trials. Indeed, most of the rhabdomyosarcoma O-PDX tumours were sensitive to AZD1775, whether they were obtained at diagnosis or recurrence ( Supplementary Table 6 ).
To establish a clinically relevant mouse-equivalent dose for bortezomib (proteasome inhibitor), panobinostat (histone deacetylase inhibitor), and AZD1775 (WEE1 inhibitor), we performed plasma and Preclinical phase I studies were performed on athymic nontumour-bearing mice to establish the tolerability of the drug combination at clinically relevant doses and schedules 14, 15 . We used O-PDXs derived from two high-risk ERMS tumours that were resected at recurrence (SJRHB000026_X1 and SJRHB012_Y) and a high-risk ARMS tumour resected at recurrence (SJRHB013759_X1) ( Supplementary Table 1 ). We introduced a luciferase reporter gene into the O-PDXs, orthotopically injected the tumour cells into immunocompromised mice and, several weeks later, enrolled the mice in a preclinical phase II trial as described previously 14, 15 . Mice were screened weekly using bioluminescence, and four to six courses (21 days per course) of therapy were administered (Extended Data Fig. 6d ). Mice with a tumour burden greater than 20% of their body weight were removed from the study and scored as progressive disease. Stable disease, partial responses, and complete responses were scored as done previously 14, 15 . All of the mice treated with panobinostat and bortezomib had progressive disease for all three O-PDX tumours tested ( Fig. 4a , b, Extended Data Fig. 6e and Supplementary Table 7 ). The mice treated with AZD1775 + VCR + IRN had a better response than those treated with VCR + IRN alone (Extended Data Fig. 6f -h and Supplementary Table 7 ).
On the basis of the activity of AZD1775 combined with VCR and IRN in multiple O-PDX rhabdomyosarcoma models, we performed a double-blind, randomized, placebo-controlled preclinical phase III study, as described previously 14, 15 . We used the same O-PDX models as above (SJRHB000026_X1, SJRHB012_Y, SJRHB013759_X1) and added another ARMS O-PDX (SJRHB013757_X2) ( Supplementary  Table 1 ). We enrolled 140 mice and randomized them to 4 treatment groups (placebo, AZD1775, VCR + IRN, and AZD1775 + VCR + IRN; Supplementary Table 8 ). Each of the O-PDX tumours had an improved outcome with the triple-drug combination relative to the standard of care (VCR + IRN), AZD1775 alone, or placebo ( Fig. 4c-f ). Individual O-PDX tumours showed marked differences in response to VCR + IRN and AZD1775 + VCR + IRN, highlighting the importance of using multiple O-PDX models for preclinical studies (Fig. 4e , f and Supplementary Table 8 ). In addition, we performed clonal analysis on 17 O-PDX tumours from SJRHB000026_X1 mice with progressive disease in three different treatment groups (AZD1775, VCR + IRN, and AZD1775 + VCR + IRN). Fifty-nine per cent (10/17) of those tumours showed clonal selection for the minor clone ( Supplementary Table 4 ), which was similar to results from previously published data on patient tumours before and after treatment 16 .
Many of the O-PDXs that we have developed were from patients with recurrent disease, which is important because there were previously few models of recurrent paediatric solid tumours. The O-PDXs retained the molecular and cellular features of the patient tumour and the epigenetic landscape of their developmental origins. The clonal composition of the patient tumours was compared with the O-PDX tumours at early and late passages, from different sublines and distinct locations within the tumour mass. Some O-PDX tumours retained the clonal composition of the patient tumour even after several passages in mice but others underwent clonal changes. For some tumours, different sublines captured different clones from the patient tumour, suggesting that separately propagating individual sublines may be important for capturing the clonal heterogeneity in patient tumours. The drug screening identified chemotherapeutic agents that had broad activity as well as drugs that were more selective for particular cancer types. This approach led to the discovery that the combination of a WEE1 inhibitor with IRN and VCR can improve response across four different O-PDXs of high-risk rhabdomyosarcoma, including recurrent disease, relative to IRN and VCR alone. We have demonstrated clonal selection in the treated tumours, as shown previously in patients 16 and it will be important to directly relate the clonal selection in O-PDX models to patients in future studies. This is proof of principle for using O-PDX tumours for basic and translational research on paediatric solid tumours and it provides a useful platform for understanding clonal selection in recurrent disease. All of our O-PDX models and associated data are freely shared through the Childhood Solid Tumour Network (www.stjude. org/CSTN/) with no obligation to collaborate.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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Power analysis was done to estimate the sample size for the preclinical phase III study. Cell lines were obtained from American Type Culture Collection (ATCC) and their identities were validated by analysing the short tandem repeats using the Promega PowerPlex 16 system. All cell lines were confirmed to be free of mycoplasma using the ATCC Universal Mycoplasma Detection kit. The preclinical phase II study was randomized but not blinded. The preclinical phase III study was randomized and blinded. Animals. Athymic nude immunodeficient mice were purchased from Jackson Laboratories (strain code 007850). NSG mice were purchased from Jackson Laboratories (strain code 005557). C57BL/6 scid mice were purchased from Jackson Laboratories (strain code 001913). This study was performed in strict accordance with the recommendations in the Guide to Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at St. Jude Children's Research Hospital. All efforts were made to minimize suffering. All mice were housed in accordance with approved IACUC protocols. Animals were housed on a 12-12 light cycle (light on 6:00, off 18:00) and provided food and water ad libitum. Patient consent and MAST protocol. Excess, de-identified tumour material was collected from patients with solid tumours at St. Jude Children's Research Hospital in agreement with local institutional ethical regulations and institutional review board approval. Patient consent for tissue acquisition was obtained under the guidelines of the MAST protocol. Primary patient tissue processing. Primary tumour tissue was processed for implantation within 2 h of surgical resection in most cases. Primary tumour was enzymatically dissociated into a single-cell suspension and injected into an anatomically correct location for the disease type when possible. If the initial tumour sample was too small for dissociation, tumour tissue was implanted in the flank location. Initial implantation was primarily done into recipient NSG female mice with the exception of retinoblastoma, which was implanted into C57BL/6 scid mice. After engraftment and sufficient tumour growth, the tumour was harvested and passaged into athymic nude mice using the same dissociation and implantation techniques. Orthotopic injections. Bone marrow injections. To minimize distress and movement during the procedure, isoflurane gas anaesthetic was used. The mouse was placed in the supine position on a nose-cone before injection. The skin of the knee joint was prepped with alternating iodine scrubs and 70% isopropyl alcohol wipes. The prepped leg was flexed at the knee joint and secured to the work surface. The femur was palpated until the femoral condyles became visible. A 25-gauge needle on a 50 μ l Hamilton glass syringe (Hamilton catalogue number 80920) was held at a 45° angle to the mouse, and the needle tip was inserted into the femur via the femoral intercondylar notch, while retracting the patella and patella tendon medially to avoid ligament damage. The needle was advanced down to the femoral head, which was approximately 5-10 mm depending on the size of the mouse, and 10 μ l of cell suspension was slowly injected into the femur. Intramuscular injections. The mouse was restrained gently but firmly by the scruff method. The rear foot nearest to the investigator was secured beneath the little finger and lower thumb. The area to be injected was swabbed with 70% ethanol. The needle was inserted, bevel up, into the caudal thigh at a 45° angle and 50-100 μ l of cell suspension was slowly injected into the muscle while avoiding injury to the sciatic nerve.
Intravitreal injections. C57BL/6 scid mice were given general anaesthesia via isoflurane inhalation continuously at 1-3% concentration with an oxygen flow rate of 2 l min −1 . The mouse was placed under the microscope where the eye was proptosed and a small incision using the tip of an 18-gauge needle was created between the sclera and the cornea. Using a 5 μ l glass Hamilton syringe (Hamilton Company, 7633-01, 65RN), cells were injected through a 33-gauge small hub needle into the vitreous of the eye at 5 μ l per injection.
Para-adrenal injections. All ultrasound procedures were performed using a VEVO 2100 high-frequency ultrasound equipped with a MS-550S transducer running at 40 MHz. Recipient immunocompromised mice were given general anaesthesia via isoflurane inhalation continuously at 1-3% concentration with an oxygen flow rate of 2 l min −1 . Anaesthetized recipients were placed laterally on the imaging bed with left flank facing upwards. To provide a channel for delivery of the implant, a 22-gauge catheter (BD Worldwide, catalogue number 381423) was gently inserted through the skin and back muscle into the para-adrenal region and the hub was removed. A chilled 50 μ l Hamilton glass syringe (Hamilton catalogue number 80920) fitted with a 27-gauge 1.5 inch needle was loaded with 10 μ l of suspension and guided stereotactically through the catheter and positioned between the kidney and adrenal gland using ultrasound. The cell suspension was then injected into the region and the needle was left in place for 30 s to allow the Matrigel component to set. The needle was then slowly removed, followed by gentle removal of the catheter. The mouse was placed in a clean cage on a warmer to recover from anaesthesia.
Flank implantation. For some tumour with sufficient material, we implanted tissue into the flank of immunocompromised mice as a backup to the orthotopic injection. Recipient immunocompromised mice were given general anaesthesia via isoflurane inhalation continuously at 1-3% concentration with an oxygen flow rate of 2 l min −1 . The mouse was placed ventral side down with a nose-cone to provide continuous anaesthesia. The area from mid-spine to the tail base was cleaned with 70% ethanol. A small horizontal 5 mm incision in the flank area was made using sterile small surgical scissors. The tip of the sterile scissors was inserted into the incision, directly over the flank, and the scissors were opened to introduce a pocket in the subcutaneous space. One individual piece of tumour tissue was inserted into the pocket using sterile forceps. One drop of 100× penicillin/streptomycin solution was inserted into the opening over the tissue piece. The incision was closed with Vetbond tissue adhesive (3M catalogue number 1469SB). The overlying skin was held together for 3-5 s with forceps to allow adequate time for drying. Enzymatic tumour dissociation. Neuroblastoma. Tumour was minced with sterile scalpels and rinsed in phosphate buffered saline without calcium or magnesium (PBS-minus solution). Tumour suspension was transferred to a 50 ml conical tube and filled with PBS-minus solution. Dissociation was done by adding 600 μ l of trypsin (10 mg ml −1 , Sigma catalogue number T9935) and the tube placed in 37 °C water bath for 10 min. Dissociation was stopped by adding 60 μ l of soybean trypsin inhibitor (10 mg ml −1 , Sigma catalogue number T6522). DNase I (2 mg ml −1 , Sigma catalogue number D4513) and magnesium chloride (1 M) were added in equal amounts of 60 μ l increments until tumour fragments easily settled at the bottom of the tube. Tumour suspension was filtered with a 40 μ m cell strainer and then centrifuged at 500g (g, relative centrifugal force) for 5 min. Supernatant was discarded and 10 ml of red blood cell lysis solution (5 Prime catalogue number 2301310) added and allowed to incubate at room temperature for 10 min. A solution of PBS-minus (Lonza catalogue number 17-516F)/10% fetal bovine serum (FBS, Biowest catalogue number SO1520) was added to fill a 50 ml conical tube and the cell suspension centrifuged at 500 g for 5 min. Supernatant was discarded and the cell pellet was resuspended in PBS-minus/10% FBS for counting. Cells were then resuspended in Matrigel basement membrane matrix (BD Biosicences catalogue number 354234) at a concentration of 2 × 10 5 cells per 10 μ l and placed on ice for injection.
Soft tissue sarcoma. Tumour was placed through a tumour press and then rinsed with Dulbecco's modified Eagle's medium (DMEM) (Lonza catalogue number 12-604F). The tumour suspension was transferred to a 50 ml conical tube and filled with DMEM. Dissociation was done by adding 600 μ l of trypsin (10 mg ml −1 ; Sigma catalogue number T9935) and 50 mg of type II collagenase (275 U mg −1 ; Worthington Biochemical catalogue number 4177), and then the tube was placed in a 37 °C water bath for 1 h. Dissociation was stopped by adding 600 μ l of soybean trypsin inhibitor (10 mg ml −1 ; Sigma catalogue number T6522). DNase I (2 mg ml −1 ; Sigma catalogue number D4513) and magnesium chloride (1 M) were added in equal amounts in 60 μ l increments until tumour fragments easily settled at the bottom of the tube. The tumour suspension was filtered with a 40 μ m cell strainer and centrifuged at 500g for 5 min. The supernatant was discarded, and 10 ml of red blood cell lysis solution (5 Prime catalogue number 2301310) was added and allowed to incubate at room temperature for 10 min. A solution of PBS-minus (Lonza catalogue number 17-516F)/10% FBS (Biowest catalogue number SO1520) was added to fill a 50 ml conical tube, and the cell suspension was centrifuged at 500 g for 5 min. The supernatant was discarded, and the cell pellet was resuspended in PBS-minus/10% FBS for counting. Cells were then resuspended in Matrigel (BD Worldwide catalogue number 354234) at a concentration of 1 × 10 6 per 100 μ l and placed on ice for injection.
Osteosarcoma. The tumour was placed through a tumour press and then rinsed with PBS-minus (Lonza catalogue number 17-516F). The tumour suspension was transferred to 100 ml screw cap glass bottle and filled with PBS-minus to the 100 ml mark. Dissociation was done by adding 600 μ l of trypsin (10 mg ml −1 ; Sigma catalogue number T9935) and 200 mg of type II collagenase (275 U mg −1 ; Worthington Biochemical catalogue number 4177), and placed in a warm 37 °C water bath for 90 min, agitating with a magnetic bead at ~ 200 r.p.m. to have all tissue circulating and lifted off the bottom of the glass bottle. Dissociation was stopped by adding 600 μ l of soybean trypsin inhibitor (10 mg ml −1 ; Sigma catalogue number T6522). DNase I (2 mg ml −1 ; Sigma catalogue number D4513) and magnesium chloride (1 M) were added in equal amounts in 60 μ l increments until tumour fragments easily settled at the bottom of the tube. The tumour suspension was filtered with a 70 μ m cell strainer and centrifuged at 500g for 5 min. The supernatant was discarded, and 10 ml of red blood cell lysis solution (5 Prime catalogue number 2301310) was added and allowed to incubate at room temperature for 10 min. A solution of PBS-minus/10% FBS (Biowest catalogue number SO1520) was letter reSeArCH added to fill a 50 ml conical tube, and the cell suspension was centrifuged at 500g for 5 min. The supernatant was discarded, and the cell pellet was resuspended in PBS-minus/10% FBS for counting. Cells were then resuspended in Matrigel basement membrane matrix (BD Biosicences catalogue number 354234) at a concentration of 1 × 10 6 cells per 10 μ l and placed on ice for injection.
Retinoblastoma. Tumour was minced with sterile scalpels and rinsed in RPMI (Lonza catalogue number 12-167F). Tumour suspension was transferred to a 50 ml conical tube and filled with RPMI. Dissociation was done by adding 600 μ l of trypsin (10 mg ml −1 , Sigma catalogue number T9935) and the tube placed in a 37 °C water bath for 10 min. Dissociation was stopped by adding 600 μ l of soybean trypsin inhibitor (10 mg ml −1 , Sigma catalogue number T6522). DNase I (2 mg ml −1 , Sigma catalogue number D4513) and magnesium chloride (1 M) were added in equal amounts of 60 μ l increments until tumour fragments easily settled at the bottom of the tube. Tumour suspension was filtered with a 40 μ m cell strainer and then centrifuged at 500g for 5 min. Supernatant was discarded and 10 ml of red blood cell lysis solution (5 Prime catalogue number 2301310) added and allowed to incubate at room temperature for 10 min. A solution of PBS-minus (Lonza catalogue number 17-516F)/10% FBS (Biowest catalogue number SO1520) was added to fill a 50 ml conical tube and the cell suspension centrifuged at 500g for 5 min. Supernatant was discarded and the cell pellet was resuspended in PBS-minus/10% FBS for counting. Cells were then resuspended in RPMI at a concentration of 1 × 10 5 cells per 5 μ l for injection. Tumour cryopreservation. After dissociation, tumour cells that were not used for passaging or high-throughput screening were cryopreserved for banking and later usage. Cells were counted and resuspended in chilled FBS/10% dimethylsulfoxide (DMSO) at a concentration of 6 × 10 6 cells per 1 ml per tube for all tumour types with the exception of retinoblastoma at a concentration of 1 × 10 6 cells per 1 ml. Cryo-tubes were placed in styrofoam containers and frozen at − 80 °C for 3 days and then transferred to liquid nitrogen for long-term storage. Histopathological scoring. Histopathological features of the patient H&E-stained slides and the O-PDX-derived slides were compared for histological similarity. These patient-xenograft pairs were placed into similarity categories on the basis of evaluation of the following attributes: overall tumour cellularity, growth pattern, cytomorphology including degree of pleomorphism, and mitotic activity. The following classification system was used: same, no difference noted between patient and xenograft-derived samples; similar, changes in growth pattern and overall cellularity allowed with no difference in pleomorphism or mitotic activity; morphological shift, significant change such that the two lesions were morphologically dissimilar with significant difference in cellularity, cytomorphological features, degree of pleomorphism, growth pattern, and mitotic activity. Immunohistochemical staining and scoring. Patient samples and the matched xenograft tissues were assessed for caspase 3 (total), caspase 3 (cleaved), and Ki-67. In addition, several diagnostically delineating markers were performed on the basis of the histopathological diagnosis. These included Fli-1 (Ewing sarcoma), Vimentin (high-grade sarcoma not otherwise specified), S100-protein (liposarcoma), INI-1 (malignant rhabdoid tumour), CRX (retinoblastoma), synaptophysin (neuroblastoma), SATB2 (osteosarcoma), and myogenin and MyoD1 (rhabdomyosarcoma). In total, excluding controls, 446 immunohistochemically stained slides were reviewed and scored. Fifty-one xenograft samples were reviewed by H&E staining, as were all pertinent slides from the primary patient specimens (~ 676 H&E-stained slides). The total number of slides examined microscopically was 1,173. Formalin-fixed paraffin-embedded tissue (4 μ m in thickness) was used for staining, with appropriate positive and negative controls evaluated. The antibodies are provided in Supplementary Table 2 . Patient sample-xenograft pairs were evaluated for overall immunohistochemical concordance. Cases were considered discordant if any of the selected diagnostic markers (Fli-1, Vimentin, S100-protein, INI-1, SATB2, and CRX) were discrepant (positive versus negative in the tumour cells). Only the expected localization of staining was considered evidence of positivity (or loss of staining as is the case with INI-1). As myogenin and MyoD1 are known to display different degrees of positivity in rhabdomyosarcoma subtypes, these stains were scored to the nearest 5% of nuclear positivity. A case was considered discordant if there was > 25% discrepancy between the estimated percentages for either myogenin or MyoD1 between the patient and xenograft samples. Histology images were obtained using an Aperio ImageScope (Leica Biosystems). Electron microscopy. Tumour samples were fixed with 2.5% glutaraldehyde, 2% parqaformadehyde in 0.1 M sodium cacodylate buffer pH 7.4, and post-fixed in 2% osmium tetroxide in 0.1 M cacodylate buffer with 0.3% potassium ferrocyanide for 1.5 h. After rinsing in the same buffer, the tissue was dehydrated through a series of graded ethanol to propylene oxide, infiltrated and embedded in epoxy resin, and polymerized at 70 °C overnight. Semithin sections (0.5 μ m) were stained with toluidine blue for examination by light microscope. Ultrathin sections (80 nm) were cut and imaged using an FEI Tecnai 200Kv FEG electron microscope with an ATM XR41 digital camera.
Whole-genome sequencing. Whole-genome sequencing and library construction were performed as described previously [17] [18] [19] with the following modifications: 250-500 ng of genomic DNA was input for library construction using Illuminacompatible adapters, and four to six cycles of amplification were performed with KAPA HiFi Hotstart ReadyMix (KAPA Biosystems). Identification of singlenucleotide variants, copy number variants, structural variants, and indels was performed as described previously [17] [18] [19] . Whole-exome sequencing. Whole-exome sequencing was conducted using the SeqCap EZ HGSC VCRome (Roche) according to the manufacturer's instructions. RNA preparation and RNA-seq. RNA was isolated from individual TRIzol (Life Technologies) preparations via a phenol-chloroform extraction. Samples were first homogenized at 17,000 r.p.m. for 30 s with a tissue homogenizer (Polytron, PT10-35GT). A 1:4 volume of chloroform (Sigma) was then added to each sample and incubated at room temperature for 3 min followed by centrifugation at 12,000g at 4 °C for 15 min. The aqueous layer was then transferred to a siliconized Eppendorf tube followed by the addition of 2.0 μ l glycogen (Roche) and 500 μ l isopropanol (Fisher). Samples were incubated at room temperature for 10 min followed by centrifugation at 12,000g at 4 °C for 15 min. Samples were then washed twice with ice-cold 80% EtOH (Fisher) to remove salts, resuspended in DEPC H 2 O, and the concentration was determined with a Nanodrop (Thermoscientific). RNA was extracted from freshly isolated retinas using an RNeasy Plus Mini kit (Qiagen catalogue number 74134). Libraries were prepared from approximately 500 ng total RNA with a TruSeq Stranded Total RNA Library Prep Kit according to the manufacturer's directions (Illumina). Paired-end 100-cycle sequencing was performed on HiSeq 2000 or HiSeq 2500 sequencers, according to the manufacturer's directions (Illumina). Gene-based FPKM quantification in RNA-seq was performed as described previously 1 . Spearman correlations were calculated for each primary tumour-O-PDX pair. Clonal analysis. Targeted enrichment was performed using a Seqcap EZchoice Kit (Roche) according to the vendor's instructions for the KAPA workflow with 500 ng of genomic DNA as the starting input for library construction. Clonal analysis was performed as described previously 1 . To test for clonal changes within different regions of a single tumour, a subset of orthotopic xenograft tumours were harvested for segmental clonal analysis. The excised tumour was cut in half with the cut edge facing upwards. Each tumour half was visually segmented into four quadrants and a biopsy punch needle was used to sample the tissue in each quadrant, producing eight samples from a single tumour. Clonal analysis was performed for each of the eight quadrant samples as described above. Samples were divided into four groups on the basis of the tumour clonal evolution between primary and O-PDX tumours: group 1 O-PDX tumours retained the clonal structure of the primary tumour; group 2 O-PDX tumours acquired significant amount of new mutations compared with the matching primary tumour; a minor clone in the primary tumour was lost in O-PDX tumours in group 3 samples; in group 4 samples, O-PDX tumours were derived from a minor clone in the primary tumour. ChIP-seq. SJRHB000026_X1, SJRHB010463_X16, SJOS001112_X1, and SJNBL046_X were submitted to Active Motif for ChIP-seq for nine histone marks (H3K27Ac, H3K27me3, H3K36me3, H3K4me1, H3K4me2, H3K4me3, H3K9-14Ac, H3K9me2, H3K9me3), RNA Pol II, CTCF, and BRD4. We first used BWA (version 0.5.9-r26-dev, default parameter) to align the ChIP-seq reads to human genome hg19 (GRCh37-lite). Picard (version 1.65(1160)) was then used for marking duplicated reads. Non-duplicated reads were kept for analysis by samtools (parameter '-q 1 -F 1024' version 0.1.18 (r982:295)). We followed the ENCODE quality control criteria and used SPP (version 1.11) to draw crosscorrelation, and calculated relative strand correlation values in R (version 2.14.0) with the packages caTools (version 1.17) and bitops (version 1.0-6) and estimated the fragment size. We required > 10 million unique mapped reads for point-source factors (H3K4me2/3, H3K9/14Ac, H3K27Ac, CTCF, RNA Pol II, BRD4) and relative strand correlation values > 1. We required 20 million unique mapped reads for broad markers (H3K9me3, H3K27me3, H3K36me3). We required 10 million unique mapped reads for INPUTs and relative strand correlation values < 1. We noticed H3K4me1 is point-source factor at some stages while it is a broad mark in others. Therefore, we treated H3K4me1 as a broad mark in quality control analyses. Then, upon manual inspection of the cross-correlation plot generated by SPP, the best fragment size estimated (the smallest fragment size estimated by SPP in all our cases) was used to extend each read and generate a bigwig file to view on IGV (version 2.3.40). All profiles were manually inspected for clear peaks and good signal-to-noise separation. Chromo-HMM. Non-duplicated aligned reads were extended by fragment size as defined above, and ChromHMM (version 1.10, with '-colfields 0,1,2,5 -center' for BinarizeBed) was used for chromatin state modelling. To choose the state number, we first modelled all mouse development stages together from 7 states to 33 states and selected the model with 16 states upon manual inspection. For better visualization of the dynamics of HMM state across stages, we normalized colour letter reSeArCH intensity by the maximum total percentage of a state covering a gene and flanking region. To determine the best region representing a gene, we first filter annotated isoforms by TSS within 2 kb of any H3K4me3/H3K4me2/H3K27Ac/H3K9-14Ac peaks at any development stage; then we selected the highest expressed isoform at any development stage estimated by cuffdiff or the longest isoform if no expression level estimated by cuffdiff. Lastly, we reduced the interval for an HMM state to half bar and the intensity to half the normalized amount if it did not rank in the top 2 HMM state for a gene. As HMM states could be assigned by multiple genes, the maximum total percentage across genes was used for normalization.
Percentages of HMM states were calculated for individual genes across four tumours with ChIP-seq profiles. Tumour-type-specific upregulated genes were selected on the basis of the following criteria: differentially expressed among tumour types (false discovery rate < 0.05), highly expressed in the specific tumour type (FPKM > 8), and highly overexpressed compared with other tumours (at least fourfold higher). Tumour-type-specific repressed genes were selected as follows: differentially expressed among tumour types (false discovery rate < 0.05), highly expressed in at least one other tumour type (FPKM > 8), and highly repressed compared with other tumours (at least fourfold lower). Tumour-type-specific epigenetically regulated genes were selected as tumour-specific upregulated or repressed genes with at least one state with a fraction change ≥ 0.25 between the specific and other tumours. Statistical analysis. The P values were adjusted for multiple comparisons using the Benjamini and Hochberg method 20 . To compare engraftment efficiency, we used MedCalc software (https://www.medcalc.org/calc/comparison_of_proportions. php) to compare proportions using the N − 1 χ 2 test as recommended in refs 21, 22. To compare time to engraftment, we used the comparison of means on MedCalc. Pre-study consultation for the preclinical phase III study was done with the Department of Biostatistics at St. Jude Children's Research Hospital. The data include a total of 140 mice treated in 4 different treatment groups from 4 O-PDX models. The goal of the study was to assess and compare the tumour response and tumour progression-free survival among treatment groups. Mice were randomized into each treatment group with a randomization code provided by the Department of Biostatistics. The survival curves of time to tumour progression were generated by the Kaplan-Meier method. log-rank tests were used to compare survival curves in each sub-group. Tumour response was defined by bioluminescence at the end of therapy as described below. If a mouse was taken off study at any point after enrolment because its tumour size was greater than 20% of its weight, it was automatically assigned a response of progressive disease. Bioluminescence signals less than 10 5 photons s −1 cm −2 sr −1 were classified as a complete response. Animals with a signal between 10 5 -10 6 photons s −1 cm −2 sr −1 were classified as having partial response. Stable disease was the same as enrolment signal, 10 6 -10 8 photons s −1 cm −2 sr −1 , and progressive disease was greater than 10 8 photons s −1 cm −2 sr −1 .
The observed response data are recorded in Supplementary Tables 7 and 8 . The results showed that the triple combination AZD1755 + IRN + VCR had the highest complete response rate 40% (4/10) for SJRHB013757_X2, 90% (9/10) for SJRHB013759_X1, 37.5% (3/8) for SJRHB000026_X1, 22% (2/9) for SJRHB012_Y, 65% (13/20) for both ARMS O-PDXs, and 29% (5/17) for both ERMS O-PDXs combined. Time to tumour progression was defined as the time interval between the date of enrolment and the date of the tumour size being > 20% of mouse weight or Xenogen signal > 10 8 at the end of study. The survival probabilities at days 25, 66, and 126 for treatment groups are available upon request. Again, the triple combination AZD1755 + IRN + VCR had the highest progression-free survival probabilities; at the end of study (day 126) these were 100%, 100%, 62.5%, 55.6%, 100%, and 59% for SJRHB013757_X2, SJRHB013759_X1, SJRHB000026_X1, SJRHB012_Y, alveolar combined, and embryonal combined, respectively.
A subset of the Kaplan-Meier survival curves is given in Fig. 4 and the others are available upon request with log-rank test P values (all log-rank test P values were 0 for the comparisons among the four treatment groups for all studies). Cell screening. Plating density and DMSO sensitivity. Cells from each tumour model were plated on a flat-bottomed, white 384-well plate (Corning catalogue number 8804BC), at 6-8 different cell densities ranging from 125 cells per well to 15,000 cells per well. Twenty-four hours after plating, cells were treated with varying DMSO concentrations (0%, 0.083%, 0.197%, and 0.443%), resulting in 12 wells per cell density at a given DMSO concentration. Seventy-two hours after the addition of DMSO, CellTiter-Glo (Promega catalogue number G7573) reagent was added at 25 μ l per well and the plate was read using a PerkinElmer EnVision plate reader. The relative light unit (RLU) signal was processed to determine which plating density yielded optimal signal-to-noise separation while maintaining logarithmic growth at 72 h after plating and minimal DMSO sensitivity.
Positive control compound selection. Cells from each tumour model were plated in a 384-well plate at optimal density as determined above. Twenty-four hours after plating, cells were drugged with a compound plate containing 6 positive control compound candidates (doxorubicin HCl, staurosporine, etoposide, SN-38, bortezomib, and cycloheximide) arrayed at a high single-point concentration and in a 1:3 serial dilution series (16 points per series). At 72 h after drugging, the plate was read using the CellTiter-Glo protocol described above. Positive controls were selected on the basis of the compound's ability to achieve complete cell killing (RLUs near background levels) with a well-defined, sigmoidal dose-response curve shape. We selected staurosporine (primary) and bortezomib (secondary) as the positive controls for all drug sensitivity experiments.
Assay validation. For each tumour model, we assessed the variability of the assay in 384-well plates by running the CellTiter-Glo assay using three independent plates with alternating maximum/minimum/middle control signals on at least two different days, and then examined Z′ and other relevant statistics. The maximum signal corresponded to cells treated with DMSO only; the minimum signal had cells treated with about 30 μ M staurosporine; and the middle signal used the cell-line-specific EC 50 value for staurosporine determined during the positive control selection described above. In general, we observed no systematic location-dependent effect across wells, the three signal levels were well separated, and Z′ values were above 0.4.
Cell culture experiments in dose-response. Cell lines were prepared by standard cell culture techniques. Xenograft cells were obtained from freshly dissociated tumours. Cell lines and O-PDX cells were counted and plated in 384-well plates (Corning catalogue number 8804BC); plating densities and plating conditions are shown in Supplementary Table 6 . Twenty-four hours after plating, each cell line or O-PDX sample was drugged with both a compound plate(s) and a positive control plate using a Biomek FX (Beckman Coulter) liquid handler equipped with a pin tool. Compounds were obtained as dry powder and dissolved in DMSO to a target concentration of either 10 mM or 2 mM (for compounds with reported high cellular potency or solubility limitations). The pin tool transferred about 65 nl of compound stock, resulting in approximately 370-fold compound dilution. At 72 h after drugging, cells were lysed with the addition of 25 μ l per well CellTiter-Glo reagent as described above. The compound plate contained compounds dissolved in DMSO arrayed in a 1:3-fold dilution series in columns 1-20 with 32 compounds per plate. The positive control plate was empty from columns 1-20; in columns 21-24, it contained single-point and 1:3 serial dilutions of the primary and secondary positive controls (staurosporine and bortezomib, respectively) dissolved in DMSO to give about 10 mM top stock concentration, and wells containing DMSO alone (negative control). There were three technical replicates per biological replicate. The purity of each compound used in these studies was verified to be > 95% using ultraviolet total wavelength content (UV TWC ) and evaporative light-scattering detection spectroscopy, and the concentration of each solution was quantified using nitrogen chemo-luminescence where possible. Cell screening analysis. Raw data processing: log 2 (RLU dose-response) fits. Raw luminescence RLU values for each compound at each concentration were log 2 transformed and normalized to obtain the percentage activity using the following equation: 100 × [(mean(negctrl) -compound)/(mean(negctrl) − mean(posctrl))]. They were then pooled from replicate experiments before fitting. Here, negctrl and posctrl refer to the negative and positive controls on each plate. Outliers for controls were detected using the robust statistic (below the [first quartile − 1.5 × IQR] or above the [third quartile + 1.5 × IQR], where IQR = interquartile range), and removed before calculating mean values.
Quality control metrics. The Z′ statistic was calculated using the following formula: 1 − ((3 × sd(negctrl)) + (3 × sd(posctrl)))/abs(mean(negctrl) − mean(posctrl)). Outliers among the negative and positive controls were removed as described above before the calculation of the mean and standard deviation statistics. Of the 1,960 plates screened in total for this project, 49 (2.5%) had Z′ < 0 and were excluded from further analysis. Of the remaining plates, the average Z′ was 0.57, and 95% of all plates had Z′ between 0.27 and 0.82.
Fitting log 2 (RLU dose-response) curves. Dose-response curves were fitted using the drc 23 package in R 24 . Both a three-parameter (with y 0 , the response without drug, set to zero) and a four-parameter model (y 0 allowed to vary) were fitted using the sigmoidal function LL2.4. The hill slope was constrained to be between − 10 and 0, and EC 50 was constrained to be between 10 −10 and 10 −4 (which equated to the drug concentration range tested in these experiments). For the three-parameter model, y Fin , the maximum response of the dose-response curve, was constrained to be between zero and the maximum of the median activities calculated at each concentration over all pooled measurements. For the four-parameter model, y 0 and y Fin were both constrained to be between the minimum and the maximum of the median activities calculated at each concentration over all pooled measurements. Values from the highest concentration tested for each compound were weighted at 10% to reduce curve fitting artefacts. The model with the lowest corrected Akaike information criterion was selected as the best fit model. Area under the curve (AUC) was calculated from the fitted curve using the trapezoid rule. In the event of a failure to fit a sigmoidal dose-response letter reSeArCH curve, the smooth.spline option in R was used to fit a curve that could be used to determine AUC.
Growth rate determination. Growth rates for each tumour cell model in this study were determined by quantifying RLU values at days 1-4 after cell plating at densities ranging from 39 to 15,000 cells per well. RLU values were log 2 transformed to fit a linear model with the y intercept constrained to zero. The resulting slope was the change in log 2 (RLU signal) per day. A value of 1 meant one doubling of RLU signal per day.
Dose-response analysis based on observed growth rate. We fitted a threeparameter model using the sigmoidal function LL2.4 in the drc package by regressing against the 'observed growth rate' as a function of concentration. The observed growth rate was calculated by estimating x 0 from x ctrl (given the growth rate of a specific tumour model as determined above, and the number of days of growth (4 days in these experiments)), and then determining the growth rate required to produce x(c), the cell count in the presence of drug at concentration c at the end of the experiment (4 days). We assumed cell count was proportional to RLU, and thus performed all calculations using RLU. For these regressions, the value of y 0 was set to the growth rate for untreated cells and the following constraints were used: 10 ≤ hill slope ≤ 0; minimum of the median observed growth rate in the presence of drug calculated at each concentration over all pooled measurements ≤ y Fin ≤ growth rate for untreated cells; 10 −10 ≤ EC 50 ≤ 10 −4 . As before, observed growth rates from the highest concentration tested for each compound were weighted at 10% to reduce curve fitting artefacts. Two useful metrics were calculated from the dose-response curves on the basis of observed growth rates. ED 0 was the effective dose required to achieve zero growth, or cytostatic behaviour. For curves that never reached zero observed growth rate, this value was set to the highest concentration tested. For curves from tumour models with a negative growth rate, this value was set to the lowest concentration tested. The second metric, AUC 0, was the area under the curve where the observed growth rate dose-response curve was below zero. Pharmacokinetics. AZD1775. The total plasma and tumour homogenate pharmacokinetics of AZD1775 in female tumour-bearing athymic nude mice (Jax Laboratories, aged 8-16 weeks) was assessed after a single oral gavage dose of 120 mg per kg (body weight). AZD1775 (AbMole, M2143, purity > 98%, molecular mass 500.60) was suspended in 0.5% methylcellulose (type 400 cPs, Sigma) at a nominal concentration of 12 mg ml −1 for a 10 ml kg −1 gavage volume. Mice were euthanized using an IACUC-approved method at 30 min and 1, 2, 4, and 8 h after dose, with three mice per time point. Whole blood was collected with sodium heparin via cardiac puncture, immediately centrifuged to plasma, and stored on dry ice for the remainder of study. Mice were then perfused with PBS via the aorta, the RMS orthotopic xenografts excised from the hind limb, rinsed with PBS, and placed on dry ice. At the end of the in vivo procedures, all samples were transferred from dry ice and placed at − 80 °C until analysis. Total plasma and tumour homogenate AZD1775 concentrations were assessed using a sensitive and specific liquid chromatography, tandem mass spectrometry assay. First, tumour samples were macerated, diluted with a 5:1 volume of Ringer solution (Frey Scientific), and homogenized with a bead-based technique 7 on a FastPrep-24 system (MP Biomedicals, Santa Ana, California, USA). Steel lysing matrix beads (MP Biomedicals, Metal Bead Lysing Matrix, 3 mg mg −1 of tumour) were added to the microcentrifuge tubes containing samples. The samples were then subjected to three vibratory cycles of 60 movements per second of 1 min each on a FastPrep-24 system. To prevent overheating due to friction, samples were placed on wet ice for 5 min between each cycle. The homogenates were then stored at − 80 °C until analysis. AZD1775 (AbMole, M2143, purity > 98%) stock solutions were prepared in methanol and used to spike matrix calibrators and quality controls. Plasma and tumour homogenate samples, 25 μ l each, were protein precipitated with 100 μ l of 5 ng ml −1 crizotinib (ApexBio, A8802, Batch 1, purity > 99%) in methanol as an internal standard. A 2 μ l aliquot of the extracted supernatant was injected onto a Shimadzu LC-20ADXR high-performance liquid chromatography system via a LEAP CTC PAL autosampler. The liquid chromatography separation was performed using a Phenomenex Synergi Hydro-RP 80Å LC column (4.0 μ m, 30 mm × 2.0 mm) maintained at 60 °C with gradient elution at a flow rate of 0.35 ml min −1 . The binary mobile phase consisted of 0.1% formic acid in ultrapure water in reservoir A and 0.1% formic acid in methanol in reservoir B. The initial mobile phase consisted of 5% B with a linear increase to 70% B in 1.5 min. The column was then rinsed for 2.5 min at 100% B and then equilibrated at the initial conditions for 2 min for a total run time of 6 min. Under these conditions, the analyte and internal standard eluted at 0.98 and 0.93 min, respectively. Analyte and internal standard were detected with tandem mass spectrometry using a SCIEX API 5500 Q-TRAP in positive ESI mode with monitoring of the following mass transitions: AZD1775 501.20 → 442.20, crizotinib 450.10 → 260.20. The method qualification and bioanalytical runs all passed our acceptance criteria for non-good laboratory practice assay performance. A quadratic model (1/x 2 weighting) fitted the calibrators across the 0.5-100 ng ml −1 range, with a correlation coefficient (R) of ≥ 0.9982. The lower limit of quantitation (LLOQ), defined as a peak area signal-to-noise ratio of 5 or greater verses a matrix blank with internal standard, was 0.5 ng ml −1 . The intra-run precision and accuracy was < 6.28% coefficient of variance and 88.2-107%, respectively.
The resultant AZD1775 concentration-time (C t ) data were grouped by matrix and time point, and summary statistics (arithmetic mean, standard deviation, %CV, minimum, median, maximum) generated using R software 8 . The AZD1775 arithmetic mean C t data for each matrix were then subjected to non-compartmental pharmacokinetic analysis (NCA) using Phoenix WinNonlin 6.4 (Certara USA, Princeton, New Jersey, USA). The extravascular model (Model 202) was applied, and area under the C t curve (AUC) values were estimated using the 'linear up log down' method. The terminal phase was defined as the three time points at the end of the C t profile, and the elimination rate constant (K e ) was estimated using an unweighted log-linear regression of the terminal phase. The terminal elimination half-life (T 1/2 ) was estimated as 0.693/K e , and the AUC from time 0 to infinity (AUC inf ) was estimated as the AUC to the last time point (AUC last ) + predicted C last /K e . Other NCA parameters estimated included observed maximum concentration (C max ), time of C max (T max ), concentration at the last observed time point (C last ), time of C last (T last ), apparent clearance (CL/F = dose/AUC inf ), and apparent terminal volume of distribution (V z /F). The average concentration over a dosing interval (C avg ) was estimated as AUC inf /dosing interval in hours. The apparent partition coefficient of AZD1775 from the plasma to tumour (K p, tumour ) was estimated as the ratio of the AUC inf, tumour to AUC inf, plasma when available. To estimate a clinically relevant mouse dosage, the resultant mouse plasma AUC inf and C avg were compared with the reported human plasma pharmacokinetic values at the putative single-agent AZD1775 maximum tolerated dose or phase 2 recommended dose 25 . All inferences were made under the assumption of timeindependent, linear, and dose-proportional pharmacokinetics in mice and humans.
Bortezomib. The total plasma and tumour pharmacokinetics of bortezomib in tumour-bearing female athymic nude mice (Jax Laboratories, aged 8-16 weeks) was assessed after a single intraperitoneal injection of 1 mg per kg (body weight). Bortezomib (LC Labs, lot BBZ-106, purity > 99%, molecular mass 384.24) was dissolved in DMSO and further diluted with 0.9% sodium chloride for injection, United States Pharmacopeia (normal saline, Baxter) for a final nominal concentration of 0.1 mg ml −1 in 2% DMSO/98% normal saline and a 10 ml per kg (body weight) injection volume. The intraperitoneal route was found to be a convenient method, given the intermittent twice-weekly dosing required in efficacy studies. Mice were euthanized using an IACUC-approved method at 10 min and 1, 3, 24, and 72 h after dose, with three mice per time point. Whole blood was collected with sodium heparin by cardiac puncture, immediately centrifuged to plasma, and stored on dry ice for the remainder of study. Mice were then perfused with PBS via the aorta, the RMS orthotopic xenograft tumours excised, rinsed with PBS, and placed on dry ice. At the end of the in vivo procedures, all samples were transferred from dry ice and placed at − 80 °C until analysis. Total plasma and tumour homogenate bortezomib concentrations were assessed using a sensitive and specific liquid chromatography, tandem mass spectrometry assay. First, tissue samples were macerated, diluted with a 5:1 volume of ultrapure water, and homogenized with a bead-based technique 26 on a FastPrep-24 system (MP Biomedicals, Santa Ana, California, USA). Ceramic lysing matrix beads (MP Biomedicals, Ceramic Bead Lysing Matrix, 3 mg mg −1 of tissue) were added to the microcentrifuge tubes containing tumour samples. Samples were then subjected to three vibratory cycles of 60 movements per second of 1 min each on a FastPrep-24 system. To prevent overheating due to friction, samples were placed on wet ice for 5 min between each cycle. The homogenates were then stored at − 80 °C until analysis. Bortezomib (LC Labs, BBZ-106, purity > 99%) stock solutions were prepared in 80% methanol/20% ultrapure water with 0.1% formic acid and used to spike matrix calibrators and quality controls. Plasma and tissue homogenate samples, 25 μ l each, were treated with 10 μ l of internal standard (bortezomib-d8, Toronto Research Chemicals, 3-GBH-170-2, purity 98%) 50 ng ml −1 spiking solution, and then protein precipitated with 100 μ l of acetonitrile with 0.1% formic acid, vortexed vigorously for 1 min, and centrifuged at 4 °C and 13,000g for 5 min. A 3 μ l aliquot of the extracted supernatant was injected onto a Shimadzu LC-20ADXR high-performance liquid chromatography system via a Shimadzu SIL-20ACXR autosampler. The liquid chromatography separation was performed using a Phenomenex Luna C8 80Å LC column (4.0 μ m, 30 mm × 2.0 mm) maintained at ambient temperature with gradient elution at a flow rate of 0.25 ml min −1 . The binary mobile phase consisted of 0.1% formic acid in ultrapure water in reservoir A and 0.1% formic acid in acetonitrile in reservoir B. The initial mobile phase consisted of 30% B with a linear increase to 100% B in 2 min. The column was then rinsed for 2.5 min at 100% B and equilibrated at the initial conditions for 2 min for a total run time of 6.5 min. Under these conditions, the analyte and internal standard eluted at 2.56 and 2.53 min, respectively. Analyte and internal standard were detected with letter reSeArCH tandem mass spectrometry using a SCIEX API 4000 in positive ESI mode with monitoring of the following mass transitions: bortezomib 367.4 → 226.2, bortezomib-d8 374.8 → 234.0. The experimental bioanalytical runs were all found to be acceptable for a singlicate non-good laboratory practice, preclinical pharmacokinetic assessment. A linear model (1/x 2 weighting) fitted the calibrators across the 1-100 ng ml −1 range, with R ≥ 0.99. Above the calibration range, quality control samples were diluted with adequate precision and accuracy. The LLOQ was 1 ng ml −1 for plasma and 6 ng ml −1 for tissues because of the dilution factor. The intra-run precision and accuracy was < 5.56% coefficient of variance and 87.1-107%, respectively, across the matrices. The resultant bortezomib C t data were grouped by matrix and time point, and manual imputation of data below the lower limit of quantitation (BLOQ) was as follows: if at any time point at least two-thirds of the C t results were above the LLOQ, the BLOQ data were replaced with a value of ½ LLOQ, else the entire time point's data were treated as missing. Then, using Phoenix WinNonlin 6.4 (Certara USA, Princeton, New Jersey, USA), C t data summary statistics (arithmetic mean, standard deviation, %CV, minimum, median, maximum) were generated, and the bortezomib arithmetic mean C t data for each matrix were subjected to NCA. The extravascular model (Model 202) was applied, and AUC values were estimated using the 'linear up log down' trapezoidal rule. The terminal phase was defined as the two to three time points at the end of the C t profile, and K e was estimated using an unweighted log-linear regression of the terminal phase. T 1/2 was estimated as 0.693/K e , and AUC inf was estimated as the AUC to the last time point (AUC last ) + predicted C last /K e . Other NCA parameters estimated included observed maximum concentration (C max ), time of C max (T max ), concentration at the last observed time point (C last ), time of C last (T last ), apparent clearance (CL/F = dose/AUC inf ), and apparent terminal volume of distribution (V z /F). The average concentration over a dosing interval (C avg ) was estimated as AUC inf /dosing interval in hours. The apparent partition coefficient of bortezomib from the plasma to the tissue of interest (K p, tissue ) was estimated as the ratio of the AUC inf, tissue to AUC inf, plasma when available. To estimate a clinically relevant mouse dosage, the resultant mouse plasma AUC inf and C avg were compared with the reported human plasma pharmacokinetic values at the putative single-agent bortezomib maximum tolerated dose at 1.3 mg m −2 intravenously on day 11 of therapy 27 . All inferences were made under the assumption of time-independent, linear, and dose-proportional pharmacokinetics in mice and humans.
Panobinostat. The total plasma and tissue pharmacokinetics of panobinostat in female tumour-bearing athymic nude mice (Jax Laboratories, aged 8-16 weeks) was assessed after a single intraperitoneal injection of 20 mg per kg (body weight). Panobinostat (LC Labs, lot PNB-101, purity > 99%, molecular mass 349.43) was suspended as the free base form in dextrose 5% for injection, United States Pharmacopeia (D5W, Baxter) at a nominal concentration of 2 mg ml −1 for a 10 ml per kg (body weight) injection volume. The intraperitoneal route was chosen given the low oral bioavailability reported in rodents 28 , and as it appeared to be the preferred route in reviewed mouse studies 29, 30 . Mice were euthanized using an IACUC-approved method at 15 min, 40 min, and 2.25, 8, and 24 h after dose, with three mice per time point. Whole blood was collected with sodium heparin by cardiac puncture, immediately centrifuged to plasma, and stored on dry ice for the remainder of study. Mice were then perfused with PBS via the aorta, the RMS orthotopic xenografts and tissues excised, rinsed with PBS, and placed on dry ice. At the end of the in vivo procedures, all samples were transferred from dry ice and placed at − 80 °C until analysis. Total plasma and tissue homogenate panobinostat concentrations were assessed using a sensitive and specific liquid chromatography, tandem mass spectrometry assay. First, tissue samples were macerated, diluted with a 5:1 volume (for tumour and brain) or a 3.1-7.0:1 volume (for varying masses of retina and vitreous) of ultrapure water, and homogenized with a bead-based technique 7 on a FastPrep-24 system (MP Biomedicals, Santa Ana, California). Ceramic lysing matrix beads (MP Biomedicals, Lysing Matrix D, 10 mg mg −1 of tissue) were added to the microcentrifuge tubes containing samples. The samples were then subjected to three vibratory cycles of 60 movements per second of 1 min each on a FastPrep-24 system. To prevent overheating due to friction, samples were placed on wet ice for 5 min between each cycle. The homogenates were then stored at − 80 °C until analysis. Panobinostat (LC Labs, lot PNB-101, purity > 99%) stock solutions were prepared in methanol and used to spike matrix calibrators and quality controls. Plasma and tissue homogenate samples, 25 μ l each, were protein precipitated with 100 μ l of 240 ng ml −1 panobinostat-d8 hydrochloride salt (Toronto Research Chemicals, P180502, lot 5-KSS-175-5, purity 96%) in methanol as an internal standard. A 2 μ l aliquot of the extracted supernatant was injected onto a Shimadzu LC-20ADXR high-performance liquid chromatography system via a LEAP CTC PAL autosampler. The liquid chromatography separation was performed using a Waters XBridge BEH C18 LC column (2.5 μ m, 75 mm × 2.1 mm) maintained at 60 °C with gradient elution at a flow rate of 0.35 ml min −1 . The binary mobile phase consisted of ultrapure water-100 mM ammonium formate, pH 3.0-methanol (850:50:100 v/v) in reservoir A, and methanol-acetonitrile-100 mM ammonium formate, pH = 3.0 (475:475:50 v/v) in reservoir B. The initial mobile phase consisted of 42.5% B and was maintained for 1.6 min. The column was then rinsed for 1.4 min at 100% B and then equilibrated at the initial conditions for 2 min for a total run time of 5 min. Under these conditions, the analyte and internal standard eluted at 0.85 and 0.83 min, respectively.
Analyte and internal standard were detected with tandem mass spectrometry using a SCIEX API 5500 Q-TRAP in positive ESI mode with monitoring of the following mass transitions: panobinostat 350.18 → 158.18, panobinostat-d8 357.91 → 147. 19 . The experimental bioanalytical runs were all found to be acceptable for a singlicate non-good laboratory practice, preclinical pharmacokinetics assessment. A linear model (1/x 2 weighting) fitted the calibrators across the 5-1,000 ng ml −1 range, with R ≥ 0.99. The LLOQ was 5 ng ml −1 for plasma and 30 ng ml −1 for tissues because of the dilution factor. The intra-run precision and accuracy was < 0.312% coefficient of variance and 99.4-113%, respectively, for plasma, brain, retina, and vitreous. Tumour matrix demonstrated less favourable precision and accuracy, with values of < 1.79% CV and 108-119%, respectively. The resultant panobinostat C t data were grouped by matrix and time point, and manual imputation of the BLOQ data was as follows: if at any time point at least two-thirds of the C t results were above the LLOQ, the BLOQ data were replaced with a value of ½ LLOQ, else the entire time point's data were treated as missing. Then, using Phoenix WinNonlin 6.4 (Certara USA, Princeton, New Jersey), C t data summary statistics (arithmetic mean, standard deviation, %CV, minimum, median, maximum) were generated, and the panobinostat arithmetic mean C t data for each matrix were subjected to NCA. The extravascular model (Model 202) was applied, and AUC values were estimated using the linear trapezoidal method and the sparse sampling option. The terminal phase was defined as the three time points at the end of the C t profile, and K e was estimated using an unweighted log-linear regression of the terminal phase. T 1/2 was estimated as 0.693/K e , and the AUC from time 0 to infinity (AUC inf ) was estimated as the AUC to the last time point (AUC last ) + C last /K e . Other NCA parameters estimated included observed maximum concentration (C max ), time of C max (T max ), concentration at the last observed time point (C last ), time of C last (T last ), apparent clearance (CL/F = dose/ AUC inf ), and apparent terminal volume of distribution (V z /F). The average concentration over a dosing interval (C avg ) was estimated as AUC inf /dosing interval in hours. The apparent partition coefficient of panobinostat from the plasma to the tissue of interest (K p, tissue ) was estimated as the ratio of the AUC inf, tissue to AUC inf, plasma when available. To estimate a clinically relevant mouse dosage, the resultant mouse plasma AUC inf and C avg were compared with the reported human plasma pharmacokinetic values at the putative single-agent panobinostat maximum tolerated dose or the Food and Drug Administration-approved dose. All inferences were made under the assumption of time-independent, linear, and dose-proportional pharmacokinetics in mice and humans. Preclinical testing. Preclinical phase I. Non-tumour-bearing athymic nude mice were used for tolerability testing of the following combinations: VCR + IRN, AZD1775 + VCR + IRN, and panobinostat + bortezomib. Mice were given four cycles of chemotherapy with 21 days per cycle. The chemotherapeutic drug combinations and schedules used were designed to mimic potential human clinical trials. Each treatment group contained three mice. Vincristine was dosed by intraperitoneal injection once a week on days 1, 8, and 15. Irinotecan was dosed by intraperitoneal injection once daily on days 1-5 and 8-12. AZD1775 was dosed by oral gavage twice daily on days 1-5. Panobinostat was dosed by intraperitoneal injection once daily on days 1, 3, 5, 8, 10, and 12. Bortezomib was dosed by intraperitoneal injection once daily on days 1, 4, 8, and 11. Mouse weight and standard complete blood counts were monitored for each treatment group. The health of the animals was monitored daily throughout therapy.
Preclinical phase II. RMS orthotopic xenografts were created by injecting luciferase-labelled cells from SJRHB000026_X1 (ERMS), SJRHB012_Y (ERMS), and SJRHB013759_X1 (ARMS) into recipient CD-1 nude mice using the intramuscular injection technique previously described. Mice were screened weekly by Xenogen and the bioluminescence was measured. Mice were enrolled in the study after achieving a target bioluminescence signal of 10 6 -10 7 photons s −1 cm −2 sr −1 or greater for 2 weeks or a palpable tumour, and chemotherapy was started the following Monday. The following preclinical phase II trials (described below) were performed ( Supplementary Table 10 ). SJRHB000026_X1 (ERMS). Mice were randomized to six treatment groups: AZD1775 + VCR + IRN, AZD1775 + IRN, VCR + IRN, panobinostat + bortezomib, IRN alone, and placebo. The dose of AZD1775 was 60 mg per kg (body weight) oral gavage twice daily for days 1-5. IRN was 1.25 mg per kg (body weight) intraperitoneally once daily on days 1-5 and 8-12. Vincristine was administered at 0.38 mg per kg (body weight) intraperitoneally once daily on days 1, 8 and 15. Panobinostat was administered at 3 mg per kg intraperitoneally on days 1, 3, 5, 8, 10 and 12. Bortezomib was administered at 1 mg per kg (body weight) intraperitoneally once daily on days 1, 4, 8, and 11. Mice received four courses of chemotherapy letter reSeArCH (3 weeks per course) and bioluminescence was monitored weekly and at the end of therapy. Disease response was classified according to bioluminescence signal. Mice with a signal of 10 5 photons s −1 cm −2 sr −1 or less (similar to background) were classified as having complete response, 10 5 -10 6 photons s −1 cm −2 sr −1 as having partial response, 10 7 -10 8 photons s −1 cm −2 sr −1 (similar to enrolment signal) as having stable disease, and greater than 10 8 photons s −1 cm −2 sr −1 as having progressive disease. Mice with tumour burden at any time greater than 20% of body weight were also classified as having progressive disease. Mice were monitored daily while receiving chemotherapy. SJRHB012_Y (ERMS). The AZD1775 groups and panobinostat + bortezomib groups were tested in two separate phase II preclinical trials. In the first trial, mice were randomized to four treatment groups: AZD1775 + VCR + IRN (low-dose protracted schedule), AZD1775 + VCR + IRN (standard 5-day schedule), VCR + IRN (low-dose protracted schedule), and placebo. The second trial randomly enrolled mice into two treatment groups, panobinostat + bortezomib, and placebo. The dose of AZD1775 was 60 mg per kg (body weight) oral gavage twice daily for days 1-5. IRN was 1.25 mg per kg (body weight) intraperitoneally once daily on days 1-5 and 8-12. Another regimen of IRN was also used in these mice at 3.125 mg per kg (body weight) intraperitoneally once daily on days 1-5. These represent the two most commonly used schedules in children in the clinic. Vincristine was administered at 0.38 mg per kg (body weight) intraperitoneally once daily on days 1, 8 and 15. Panobinostat was administered at 3 mg per kg intraperitoneally on days 1, 3, 5, 8, 10 and 12. Bortezomib was administered at 1 mg per kg (body weight) intraperitoneally once daily on days 1, 4, 8, and 11. Mice received six courses of chemotherapy, and bioluminescence was monitored weekly in the first trial and with each course (every 3 weeks) in the second trial. Disease response was classified according to bioluminescence signal. Mice with a signal of 10 5 photons s −1 cm −2 or less (similar to background) were classified as having complete response, 10 5 -10 6 photons s −1 cm −2 sr −1 as having partial response, 10 7 -10 8 photons s −1 cm −2 sr −1 (similar to enrolment signal) as having stable disease, and greater than 10 8 photons s −1 cm −2 sr −1 as having progressive disease. Mice with tumour burden at any time greater than 20% of body weight were also classified as having progressive disease. Mice were monitored daily while receiving chemotherapy. SJRHB013759_X1 (ARMS). The AZD1775 groups and panobinostat + bortezomib groups were tested in two separate phase II preclinical trials. In the first trial, mice were randomized to three treatment groups: AZD1775 + VCR + IRN (low-dose protracted schedule), VCR + IRN (low-dose protracted schedule), and placebo. The second trial randomly enrolled mice into two treatment groups, panobinostat + bortezomib, and placebo. The dose of AZD1775 was 60 mg per kg (body weight) oral gavage twice daily for days 1-5. IRN was 1.25 mg per kg (body weight) intraperitoneally once daily on days 1-5 and 8-12. Vincristine was administered at 0.38 mg per kg (body weight) intraperitoneally once daily on days 1, 8 and 15. Panobinostat was administered at 3 mg per kg intraperitoneally on days 1, 3, 5, 8, 10 and 12. Bortezomib was administered at 1 mg per kg (body weight) intraperitoneally once daily on days 1, 4, 8, and 11. Mice received six courses of chemotherapy, and bioluminescence was monitored weekly in the first trial and with each course (every 3 weeks) in the second trial. Disease response was classified according to bioluminescence signal. Mice with a signal of 10 5 photons s −1 cm −2 sr −1 or less (similar to background) were classified as having complete response, 10 5-10 6 photons s −1 cm −2 sr −1 as having partial response, 10 7 -10 8 photons s −1 cm −2 sr −1 (similar to enrolment signal) as having stable disease, and greater than 10 8 photons s −1 cm −2 sr −1 as having progressive disease. Mice with tumour burden at any time greater than 20% of body weight were also classified as having progressive disease. Mice were monitored daily while receiving chemotherapy.
Preclinical phase III. We performed a randomized, double-blind placebocontrolled preclinical phase III trial using 140 mice from 4 different O-PDX lines. RMS orthotopic xenografts were created by injecting luciferase-labelled cells from SJRHB000026_X1 (ERMS), SJRHB012_Y (ERMS), SJRHB013757_X2 (ARMS), and SJRHB013759_X1 (ARMS) into recipient athymic nude mice using the intramuscular injection technique previously described. Mice were screened weekly by Xenogen and the bioluminescence was measured. Mice were enrolled in the study after achieving a target bioluminescence signal of 10 6 -10 7 photons s −1 cm −2 sr −1 or greater for 2 weeks or a palpable tumour, and chemotherapy was started the following Monday. Individuals giving the chemotherapy as well as those doing the bioluminescence imaging were blinded to the drugs being administered as well as to the specific O-PDX tumour line. The following drugs and doses were used in the preclinical phase III trial based on AUC-guided dosing obtained from pharmacokinetic studies matched to human doses that are clinically relevant in patients. The dose of AZD1775 was 48 mg per kg (body weight) oral gavage twice daily for days 1-5. IRN was 1.25 mg per kg (body weight) intraperitoneally once daily on days 1-5 and 8-12. Vincristine was administered at 0.38 mg per kg (body weight) intraperitoneally once daily on days 1, 8 and 15. Mice received six courses of chemotherapy (3 weeks per course) and bioluminescence was monitored on week 3 of each course and at the end of therapy. Disease response was classified according to bioluminescence signal as above. AZD1775 was reconstituted in 0.5% methylcellulose, IRN and VCR in sterile normal saline. Xenogen imaging and quantification. Mice were given intraperitoneal injections of firefly D-luciferin (Caliper Life Sciences 3 mg per mouse). Bioluminescent images were taken 5 minutes later using an IVIS 200 imaging system. Anaesthesia was administered throughout image acquisition (isoflurane 1.5% in oxygen delivered at 2 l min −1 ). Living Image 4.3 software (Caliper Life Sciences) was used to generate a standard region of interest encompassing the largest tumour at maximal bioluminescence signal. The identical region of interest was used to determine the average radiance (in photons s −1 cm −2 sr −1 ) for all xenografts. Data availability. All sequence data have been deposited in the European Bioinformatics Institute (EMBL-EBI) under accession number EGAS00001002528.
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Significantly Mutated neuroblastoma ALK (2) BCL11A (1) BCL6 (1) BCR (2) CIC (7) CREBBP (2) EP300 (1) ETV5 (1) EWSR1 (2) FLI1 (2) GMPS (1) HMGA2 (1) The Pearson correlation between those two variables is indicated for each tumour type. The line of best fit for the data is shown (red). e, f, Diagram and scatterplot of the clonal changes in SJOS001132 between the patient tumour and the O-PDX. The proportion of proliferating cells as measured by Ki67 immunostaining and dying cells as measured by cleaved caspase 3 immunostaining. The patient tumour had a major clone with two clusters of SNVs (C1 and C2) that then continued to evolve and diverge in the O-PDX into two distinct clones. One clone contained the original SNVs found in the patient tumour (C1 and C2) and the other clone had an additional cluster of SNVs (C3). The total number of SNVs analysed in this sample was 238. g, H&E staining of the patient tumour and the O-PDX showing an expansion of cells with more aggressive pleiomorphic cellular features. h, i, Diagram and scatterplot of the clonal changes in SJNBL124 between the patient tumour and the O-PDX. The proportion of proliferating cells as measured by Ki67 immunostaining and dying cells as measured by cleaved caspase 3 immunostaining. The patient tumour had a major clone (80% of the tumour) with one cluster of SNVs (C1) and a minor clone (20% of the tumour) with two clusters of SNVs (C1 and C2). In the O-PDX, the minor clone was lost and the tumour continued to evolve and acquired an additional cluster of SNVs (C3). The total number of SNVs analysed in this sample was 373. j, In the H&E-stained patient tumour, there was a major clone (90% of the tumour) with proliferating small round cells and a minor clone (10% of the tumour) that had features of differentiated neuroblastoma cells. The cells with features of differentiated cells were lost in the O-PDX. The pharmacokinetics for IRN and VCR had been determined previously. d, Outline of the schedule used for the combination of panobinostat with bortezomib, VCR + IRN as the standard of care and AZD1775 + VCR + IRN. The schedules were selected to match that used in patients and the dose was selected to provide the same plasma exposure based on the pharmacokinetics in a-c. e-g, Tumour response for individual SJRHB000026_X1 mice on the preclinical phase II study for placebo-treated mice and each of the three treatment groups. Each line indicates an individual mouse with tumour. h, Stack bar plots of the response percentages for three different RMS O-PDX models with standard of care for recurrent RMS (IRN + VCR) and the AZD1775 + VCR + IRN treatment regimen. The numbers of mice in each response category are indicated on the plot.
